Literature DB >> 21115631

Peritoneal membrane phosphate transport status: a cornerstone in phosphate handling in peritoneal dialysis.

Ana Paula Bernardo1, Sebastián Azorin Contesse, Maria Auxiliadora Bajo, Anabela Rodrigues, Gloria Del Peso, Marta Ossorio, António Cabrita, Rafael Selgas.   

Abstract

BACKGROUND AND OBJECTIVES: Phosphate control impacts dialysis outcomes. Our aim was to define peritoneal phosphate transport in peritoneal dialysis (PD) and to explore its association with hyperphosphatemia, phosphate clearance (PPhCl), and PD modality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Two hundred sixty-four patients (61% on continuous ambulatory PD [CAPD]) were evaluated at month 12. PPhCl was calculated from 24-hour peritoneal effluent. Phosphate (Ph) and creatinine (Cr) dialysate/plasma (D/P) were calculated at a 4-hour 3.86% peritoneal equilibration test.
RESULTS: D/PPh correlated with D/PCr. PPhCl correlated better with D/PPh than with D/PCr. Prevalence of hyperphosphatemia (>5.5 mg/dl) was 30%. In a multiple regression analysis, only residual renal function was independently, negatively associated with hyperphosphatemia; in anuric patients, only D/PPh was an independent factor predicting hyperphosphatemia. D/PPh was 0.57 ± 0.10, and according to this, 16% of the patients were fast, 31% were fast-average, 35% were slow-average, and 17% were slow transporters. PPhCl was 37.5 ± 11.7 L/wk; it was lower in the slow transporter group (31 ± 14 L/wk). Among fast and fast-average transporters, PPhCl was comparable in both PD modalities. In comparison to automated PD, CAPD was associated with increased PPhCl among slow-average (36 ± 8 versus 32 ± 7 L/wk) and slow transporters (34 ± 15 versus 24 ± 9 L/wk).
CONCLUSIONS: In hyperphosphatemic, particularly anuric, patients, optimal PD modality should consider peritoneal phosphate transport characteristics. Increasing dwell times and transfer to CAPD are effective strategies to improve phosphate handling in patients with inadequate phosphate control on automated PD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115631      PMCID: PMC3082418          DOI: 10.2215/CJN.06960810

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  20 in total

1.  The relationship between residual renal function, protein catabolic rate, and phosphate and magnesium levels in peritoneal dialysis patients.

Authors:  Denis E Pagé; Gregory A Knoll; Vincent Cheung
Journal:  Adv Perit Dial       Date:  2002

2.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

Review 3.  Fluid and electrolyte transport across the peritoneal membrane during CAPD according to the three-pore model.

Authors:  Bengt Rippe; Daniele Venturoli; Ole Simonsen; Javier de Arteaga
Journal:  Perit Dial Int       Date:  2004 Jan-Feb       Impact factor: 1.756

4.  The transport of phosphate between the plasma and dialysate compartments in peritoneal dialysis is influenced by an electric potential difference.

Authors:  J Graff; S Fugleberg; J Brahm; N Fogh-Andersen
Journal:  Clin Physiol       Date:  1996-05

Review 5.  Cardiovascular risk in the peritoneal dialysis patient.

Authors:  Raymond T Krediet; Olga Balafa
Journal:  Nat Rev Nephrol       Date:  2010-06-22       Impact factor: 28.314

6.  [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].

Authors:  P Gallar; O Ortega; M Gutiérrez; M Muñoz; L Hilara; A Oliet; I Rodríguez; E Giménez; A Vigil
Journal:  Nefrologia       Date:  2000 Jul-Aug       Impact factor: 2.033

7.  Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.

Authors:  Eric W Young; Justin M Albert; Sudtida Satayathum; David A Goodkin; Ronald L Pisoni; Takashi Akiba; Tadao Akizawa; Kiyoshi Kurokawa; Jürgen Bommer; Luis Piera; Friedrich K Port
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

8.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Authors:  Geoffrey A Block; Preston S Klassen; J Michael Lazarus; Norma Ofsthun; Edmund G Lowrie; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

9.  Cross-sectional assessment of weekly urea and creatinine clearances in patients on continuous ambulatory peritoneal dialysis.

Authors:  K D Nolph; H L Moore; Z J Twardowski; R Khanna; B Prowant; M Meyer; L Ponferrada
Journal:  ASAIO J       Date:  1992 Jul-Sep       Impact factor: 2.872

10.  Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications?

Authors:  Angela Yee-Moon Wang; Jean Woo; Mandy Man-Mei Sea; Man-Ching Law; Siu-Fai Lui; Philip Kam-Tao Li
Journal:  Am J Kidney Dis       Date:  2004-04       Impact factor: 8.860

View more
  10 in total

1.  Associations of fibroblast growth factor 23 with parameters of phosphate metabolism in incident peritoneal dialysis patients.

Authors:  Edyta Golembiewska; Krzysztof Safranow; Joanna Kabat-Koperska; Kazimierz Ciechanowski; Joanna Bober; Anna Bogacka
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

2.  Dietary phosphorus intake and distribution in Chinese peritoneal dialysis patients with and without hyperphosphatemia.

Authors:  Na Jiang; Wei Fang; Xiaoxiao Yang; Lin Zhang; Jiangzi Yuan; Aiwu Lin; Zhaohui Ni; Jiaqi Qian
Journal:  Clin Exp Nephrol       Date:  2014-09-05       Impact factor: 2.801

3.  Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.

Authors:  Tamara Isakova; Huiliang Xie; Allison Barchi-Chung; Gabriela Vargas; Nicole Sowden; Jessica Houston; Patricia Wahl; Andrew Lundquist; Michael Epstein; Kelsey Smith; Gabriel Contreras; Luis Ortega; Oliver Lenz; Patricia Briones; Phyllis Egbert; T Alp Ikizler; Harald Jueppner; Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 8.237

4.  Removal of Different Classes of Uremic Toxins in APD vs CAPD: A Randomized Cross-Over Study.

Authors:  Sunny Eloot; Raymond Vanholder; Clement Dequidt; Wim Van Biesen
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

5.  Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients?

Authors:  Merita Rroji; Saimir Seferi; Majlinda Cafka; Elizana Petrela; Erjola Likaj; Myftar Barbullushi; Nestor Thereska; Goce Spasovski
Journal:  Int Urol Nephrol       Date:  2013-04-17       Impact factor: 2.370

6.  Phosphate Removal by Peritoneal Dialysis: The Effect of Transporter Status and Peritoneal Dialysis Prescription.

Authors:  Cecile Courivaud; Andrew Davenport
Journal:  Perit Dial Int       Date:  2015-07-29       Impact factor: 1.756

7.  Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients.

Authors:  Rameez Imtiaz; Steven Hawken; Brendan B McCormick; Simon Leung; Swapnil Hiremath; Deborah L Zimmerman
Journal:  Nutrients       Date:  2017-02-17       Impact factor: 5.717

8.  Phosphate clearance in peritoneal dialysis.

Authors:  Malgorzata Debowska; Rafael Gomez; Joyce Pinto; Jacek Waniewski; Bengt Lindholm
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

9.  Effluent Osteopontin levels reflect the peritoneal solute transport rate.

Authors:  Jianzhong Li; Jingjing Lan; Qing Qiao; Lei Shen; Guoyuan Lu
Journal:  Open Med (Wars)       Date:  2021-06-07

Review 10.  Phosphate control in dialysis.

Authors:  Adamasco Cupisti; Maurizio Gallieni; Maria Antonietta Rizzo; Stefania Caria; Mario Meola; Piergiorgio Bolasco
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-10-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.